Sutro Biopharma (STRO) Interest Expenses (2017 - 2022)

Sutro Biopharma has reported Interest Expenses for 10 years, with the latest figure at -$7.1 million in Q4 2025.

• Quarterly Interest Expenses fell 2974.49% year-over-year to -$7.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$2.3 million (down 30.46% YoY) and the FY2025 annual result came in at $272.2 million, up 19.47% from the prior year.
• Interest Expenses eased to -$7.1 million in Q4 2025 per STRO's latest filing, from $19.7 million in the prior quarter.
• Over five years, Interest Expenses peaked at $40.6 million in Q2 2023 and troughed at -$7.1 million in Q4 2025.
• A 5-year average of $8.7 million and a median of $2.3 million in 2024 frame the typical range for Interest Expenses.
• The sharpest annual moves came in 2023 and 2025: Interest Expenses surged 6660.83% in 2023, then plunged 2974.49% in 2025.
• Over 5 years, Interest Expenses stood at $3.7 million in 2021, then sank by 88.38% to $427000.0 in 2022, then tumbled by 1171.19% to -$4.6 million in 2023, then jumped by 105.4% to $247000.0 in 2024, then slumped by 2974.49% to -$7.1 million in 2025.
• According to Business Quant data, Interest Expenses over the past three periods registered -$7.1 million, $19.7 million, and $22.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.